Fintel reports that Zeskind Benjamin J. has filed a 13G/A form with the SEC disclosing ownership of 3.50MM shares of Immuneering Corporation Class A (IMRX). This represents 13.1% of the company.
In their previous filing dated February 10, 2022 they reported 3.36MM shares and 12.70% of the company, an increase in shares of 4.13% and an increase in total ownership of 0.40% (calculated as current - previous percent ownership).
Analyst Price Forecast Suggests 333.94% Upside
As of February 8, 2023, the average one-year price target for Immuneering is $17.75. The forecasts range from a low of $12.12 to a high of $26.25. The average price target represents an increase of 333.94% from its latest reported closing price of $4.09.
The projected annual revenue for Immuneering is $0MM, a decrease of 65.45%. The projected annual EPS is $-2.63.
Fund Sentiment
There are 69 funds or institutions reporting positions in Immuneering. This is a decrease of 72 owner(s) or 51.06%.
Average portfolio weight of all funds dedicated to US:IMRX is 0.0705%, an increase of 355.8476%. Total shares owned by institutions decreased in the last three months by 1.92% to 12,231K shares.
What are large shareholders doing?
Price T Rowe Associates holds 3,663,492 shares representing 13.87% ownership of the company. In it's prior filing, the firm reported owning 4,142,829 shares, representing a decrease of 13.08%. The firm increased its portfolio allocation in IMRX by 35.27% over the last quarter.
Cormorant Asset Management holds 2,286,181 shares representing 8.66% ownership of the company. No change in the last quarter.
Citadel Advisors holds 2,184,909 shares representing 8.27% ownership of the company. In it's prior filing, the firm reported owning 2,199,209 shares, representing a decrease of 0.65%. The firm increased its portfolio allocation in IMRX by 133.57% over the last quarter.
PRHSX - T. Rowe Price Health Sciences Fund holds 1,620,518 shares representing 6.14% ownership of the company. In it's prior filing, the firm reported owning 1,640,387 shares, representing a decrease of 1.23%. The firm increased its portfolio allocation in IMRX by 167.28% over the last quarter.
PRNHX - T. Rowe Price New Horizons Fund holds 1,295,329 shares representing 4.91% ownership of the company. In it's prior filing, the firm reported owning 1,296,469 shares, representing a decrease of 0.09%. The firm increased its portfolio allocation in IMRX by 166.25% over the last quarter.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
